Hepatotoxicity is one of the main reasons for drug withdrawals, accounting for 37% of all therapeutics taken off the market between 1994 and 2006.
CellCiphr® Premier combines an extended panel of toxicologically-relevant endpoints with Cyprotex’s CellCiphr® classifier to provide one of the most reliable clinical hepatotoxicity predictors available (sensitivity = 70% and specificity = 100%).
Both HepG2 (replicating cells) and primary rat hepatocytes (metabolically competent cells) are investigated at multiple time points (extending from 4 hrs to 5 days to identify early and late stage toxic effects).
The data can be integrated with actual or predicted Cmax to correct for exposure-related effects.
The extended panel of end points allows CellCiphr® Premier to offer enhanced predictivity for hepatotoxicity risk over the standard CellCiphr® panels.